Public health epidemiology Maternal and child health including vaccine trials Adolescent health Non-communicable diseases Travellers health
IPH has been recognized by the Government of India’s Ministry of Science & Technology, Department of Scientific and Industrial Research (DSIR) as a Scientific and Research Organization (SIRO). IPH has also been empanelled by the Karnataka Evaluation Authority as a consultant organization for conducting public policy and program evaluation, and as a partners in the National Corporate Social (CSR) Responsibility Hub at Tata Institute of Social Sciences. IPH is also the secretariat for the Health Equity Network India and is a global secretariat for the “Emerging Voices for Global Health” network of Health Systems Global. IPH has worked closely with national and state governments in India in strengthening health systems especially in the areas of primary health care, maternal and child health, strengthening public health policies and in moving towards universal health coverage. IPH has worked closely with UNICEF and WHO Alliance for Health Policy & Systems Research in various initiatives on health systems strengthening. IPH researchers have received funding and fellowships from organisations including the Wellcome Trust/DBT India Alliance, WHO Alliance for Health Policy & Systems Research (Geneva) and various reputed national and international funding agencies thorugh highly competitive research grants. IPH has been registered under NITI Aayog (NGO Darpan), with UNICEF as a partner (partner ID 888) and is registered under the GuideStar database of non-profits. IPH is headquartered in Bangalore with field stations in various locations with ongoing fieldwork in different states. IPH has an active ethics committee that functions in accordance with the national guidelines of ethical research of the ICMR. IPH also has an active gender issues and sexual harassment committee and exercises oversight over quality of its reserch through a committee on research conduct.
We want to provide example of science validation of the capability and speed of Micar21 Drug Discovery Platform, which can be viewed and validated through science publications. Early of December no one had accurate data on the effect of the new Covid19 - UK & South Africa mutations on the action of vaccines and on the binding of the virus to ACE2, so Micar21 decided to calculate pro-bono and support science worldwide. On 16.12.2020 - Micar21 starts insilico calculations. On 26.12.2020 - first version of our science publication - with calculation for English mutation COVID19. On 31.12.2020 - second version of our science publication - with calculation for South African mutation COVID19 is included and we published our scientific publication: https://www.biorxiv.org/content/10.1101/2020.12.23.424283v2.article-metrics Dr. Filip Fratev (Micar21) is the sole author of the science publication. In less than 5 months there are already 22 citations (very good result). Our competitors appeared with insilico data for Covid19 Mutations at the end of January 2021 (can be traced through science publications) On 14.02.2021 (sent on 14.02.2021 - published on 23.02.2021) science publication by Oxford, validates Micar21 insilico results with experimental data: https://www.cell.com/cell/pdf/S0092-8674(21)00226-9.pdf Here, through the experimental data, our Micar21 insilico data calculated in December 2020 are proved. Micar21 predicted in silico the stronger N501Y mutant binding to ACE2 (-1.42 kcal/mol) whereas months later experimental data shown a value of (-1.40 kcal/mol), thus, confirming that our in silico results was precise. The aim of Micar21 study and new paper was to provide urgently high quality data about the effect of the UK and South African mutations. However, during the process of revision of the paper many experimental studies became available which was an excellent opportunity for a validation of the in silico approaches employed here and in particular protein-protein FEP. Also, we can compare our results to other data obtained by theoretical approaches which can be viewed and validated through other science publications and showed in our new science publication in Journal of Chemical Information and Modelling - under final review: http://micar21.com/Covid19_UK_SA_mutation.pdf
Arthroscopy Sports Surgery Ankle and Foot Basic Research
Big Data Machine Learning Deep Learning Bioinformatics Drug Discovery Forensics 3D Image processsing
- Additive Manufacturing - Electronics - Robots - Bio-additive manufacturing
Public Health, Engineering Field, Humanitarian Engineering Field, Educational Field and Teaching